


CLAIMS

1. A compound of Formula I



5

a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug;

wherein R<sub>1</sub> is a) -(C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with -CF<sub>3</sub>, b) -C≡C-CH<sub>3</sub>, c)

-C≡C-Cl, d) -C≡C-CF<sub>3</sub>, e) -CH<sub>2</sub>O(C<sub>1</sub>-C<sub>4</sub>)alkyl optionally substituted with -CF<sub>3</sub> or f)

10 -CF<sub>3</sub>;

R<sub>2</sub> is a) -(C<sub>1</sub>-C<sub>5</sub>)alkyl, b) -(C<sub>2</sub>-C<sub>5</sub>)alkenyl or c) -phenyl optionally substituted with one of the following: -OH, -NR<sub>9</sub>-C(O)-(C<sub>2</sub>-C<sub>4</sub>)alkyl, -CN, -Z-het, -

O-(C<sub>1</sub>-C<sub>3</sub>)alkyl-C(O)-NR<sub>9</sub>R<sub>10</sub>, -NR<sub>9</sub>-Z-C(O)-NR<sub>9</sub>R<sub>10</sub>, -Z-NR<sub>9</sub>-SO<sub>2</sub>-R<sub>10</sub>, -NR<sub>9</sub>-SO<sub>2</sub>-het, -O-C(O)-(C<sub>1</sub>-C<sub>4</sub>)alkyl or -O-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub>)alkyl;

15 Z for each occurrence is independently -(C<sub>0</sub>-C<sub>4</sub>)alkyl;

R<sub>3</sub> is a) -hydrogen, b) -(C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three halo, c) -(C<sub>2</sub>-C<sub>6</sub>)alkenyl or d) -(C<sub>2</sub>-C<sub>6</sub>)alkynyl optionally substituted with one to three halo;

R<sub>4</sub> is a) -hydrogen, b) -(C<sub>2</sub>-C<sub>5</sub>)alkyl-NR<sub>8</sub>R<sub>6</sub> or c) -(C<sub>0</sub>-C<sub>5</sub>)alkyl-het;

or R<sub>3</sub> and R<sub>4</sub> are taken together with N to form het;

20 R<sub>5</sub> and R<sub>6</sub> are each independently a) hydrogen or b) -(C<sub>1</sub>-C<sub>3</sub>)alkyl;

het is an optionally substituted 5-, 6- or 7-membered saturated, partially saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic ring; and optionally substituted with one to four R<sub>7</sub>; provided that het is other than pyridinyl, imidazolyl or tetrazolyl;

25 R<sub>7</sub> is a) -(C<sub>1</sub>-C<sub>5</sub>)alkyl optionally substituted with one to three R<sub>8</sub>, b) -Z-NR<sub>9</sub>R<sub>10</sub> or c) -Z-C(O)-NR<sub>9</sub>R<sub>10</sub>;

10006215.102601

R<sub>8</sub> for each occurrence is independently a) halo, b) -OH, c) oxo or d) -O(C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sub>9</sub> and R<sub>10</sub> for each occurrence are independently a) -H or b) -(C<sub>1</sub>-C<sub>3</sub>)alkyl; or R<sub>9</sub> and R<sub>10</sub> are taken together with N to form het;

5 provided that:

1) when R<sub>1</sub> is -C≡C-CH<sub>3</sub>, R<sub>2</sub> is phenyl and R<sub>3</sub> is hydrogen, then R<sub>4</sub> is other than -(CH<sub>2</sub>)<sub>2</sub>-N(CH<sub>3</sub>)<sub>2</sub>, -(CH<sub>2</sub>)<sub>3</sub>-N(CH<sub>3</sub>)<sub>2</sub>, -(CH<sub>2</sub>)<sub>2</sub>-pyrrolidinyl optionally substituted with methyl, -(CH<sub>2</sub>)<sub>3</sub>-pyrrolidinyl or -(CH<sub>2</sub>)<sub>2</sub>-morpholinyl;


10 2) when R<sub>1</sub> is -C≡C-CH<sub>3</sub>, R<sub>2</sub> is -CH<sub>2</sub>-CH=CH<sub>2</sub> and R<sub>3</sub> is hydrogen, then R<sub>4</sub> is other than -(CH<sub>2</sub>)<sub>2</sub>-pyrrolidinyl;

15 3) when R<sub>1</sub> is -C≡C-CH<sub>3</sub>, R<sub>2</sub> is propyl and R<sub>3</sub> is hydrogen, then R<sub>4</sub> is other than -(CH<sub>2</sub>)<sub>2</sub>-N(CH<sub>3</sub>)<sub>2</sub> or -(CH<sub>2</sub>)<sub>2</sub>-pyrrolidinyl;

4) when R<sub>1</sub> is -C≡C-CH<sub>3</sub>, R<sub>2</sub> is butyl and R<sub>3</sub> is hydrogen, then R<sub>4</sub> is other than -(CH<sub>2</sub>)<sub>2</sub>-N(CH<sub>3</sub>)<sub>2</sub>, -(CH<sub>2</sub>)<sub>2</sub>-pyrrolidinyl or -(CH<sub>2</sub>)<sub>2</sub>-morpholinyl; and

15 5) when R<sub>1</sub> is -C≡C-CH<sub>3</sub>, R<sub>2</sub> is pentyl and R<sub>3</sub> is hydrogen, then R<sub>4</sub> is other than -(CH<sub>2</sub>)<sub>2</sub>-morpholinyl or -(CH<sub>2</sub>)<sub>2</sub>-pyrrolidinyl.

2. A compound of claim 1 of Formula II



II

20 a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug;

wherein R<sub>1</sub> is a) -(C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with -CF<sub>3</sub>, b) -C≡C-CH<sub>3</sub>, c) -CF<sub>3</sub> or d) -CH<sub>2</sub>O(C<sub>2</sub>-C<sub>4</sub>)alkyl.

3. A compound of claim 2 wherein R<sub>1</sub> is a) -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, b) -C≡C-CH<sub>3</sub> or c) -

25 CF<sub>3</sub>.

4. A compound of claim 3

wherein R<sub>3</sub> is a) hydrogen, b) methyl, c) ethyl, d) propyl or e) isopropyl;

R<sub>4</sub> is -(C<sub>2</sub>-C<sub>3</sub>)alkyl-NR<sub>5</sub>R<sub>6</sub>;

R<sub>5</sub> and R<sub>6</sub> are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

5. A compound of claim 4

wherein R<sub>3</sub> is a) methyl, b) ethyl, c) propyl or d) isopropyl;

5 R<sub>4</sub> is -(C<sub>2</sub>-C<sub>3</sub>)alkyl-NR<sub>3</sub>R<sub>6</sub>;

R<sub>5</sub> and R<sub>6</sub> are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

6. A compound of claim 5

wherein R<sub>3</sub> is a) methyl or b) ethyl;

10 R<sub>4</sub> is -(C<sub>2</sub>-C<sub>3</sub>)alkyl-NR<sub>3</sub>R<sub>6</sub>;

R<sub>5</sub> and R<sub>6</sub> are each methyl.

7. A compound of claim 3

wherein R<sub>3</sub> is a) hydrogen, b) methyl or c) ethyl;

R<sub>4</sub> is -(C<sub>0</sub>-C<sub>4</sub>)alkyl-het;

15 het is a) morpholinyl, b) pyrrolidinyl, c) piperidinyl, d) piperazinyl, e)

hexahydro-azepinyl, f) azabicyclo[2.2.2]oct-3-yl, g) azabicyclo[3.2.1]oct-3-yl, h) 3,6-diazabicyclo[3.1.1]heptyl or i) 2,5-diazabicyclo[2.2.1]heptyl;

the above het groups are optionally substituted with one to four R<sub>7</sub>;

R<sub>7</sub> is a) methyl, b) ethyl or c) -NR<sub>9</sub>R<sub>10</sub>;

20 R<sub>9</sub> and R<sub>10</sub> are each independently methyl or ethyl.

8. A compound of claim 7

wherein R<sub>3</sub> is a) hydrogen, b) methyl or c) ethyl;

R<sub>4</sub> is -(C<sub>0</sub>-C<sub>3</sub>)alkyl-het;

het is a) morpholinyl, b) pyrrolidinyl, c) piperidinyl, d) hexahydro-azepinyl, or

25 e) azabicyclo[3.2.1]oct-3-yl;

the above het groups are optionally substituted with one or two R<sub>7</sub>;

wherein R<sub>7</sub> is a) methyl or b) ethyl.

9. A compound of claim 8

wherein R<sub>3</sub> is a) methyl or b) ethyl;

30 R<sub>4</sub> is -(C<sub>0</sub>-C<sub>3</sub>)alkyl-het;

het is a) pyrrolidinyl, b) piperidinyl, c) hexahydro-azepinyl, or d)

azabicyclo[3.2.1]oct-3-yl;

the above het groups are optionally substituted with one R<sub>7</sub>;

wherein R<sub>7</sub> is a) methyl or b) ethyl.

10. A compound of claim 3 wherein  $R_3$  and  $R_4$  are taken together with N to form het;  
wherein het is a) piperazinyl, b) pyrrolidinyl, c) piperidinyl, d) 2,5-diazabicyclo[2.2.1]heptyl, e) azetidinyl, f) 1,4-diazabicyclo[3.2.2]nonanyl, g) 3,6-diazabicyclo[3.2.2]nonanyl, h) octahydro-pyrido[1,2-a]pyrazinyl or i) hexahydro-1,4-diazepinyl;

5 the above het groups are optionally substituted with one or two  $R_7$ ;  
 $R_7$  is a)  $-(C_1-C_2)alkyl$  optionally substituted with one or two  $R_8$ , b)  $-(C_0-C_2)alkyl-NR_9R_{10}$  or c)  $-Z-C(O)-NR_9R_{10}$ ;

10  $R_8$  is -OH;  
 $R_9$  and  $R_{10}$  are each independently a) hydrogen b) methyl or c) ethyl;  
or  $R_9$  and  $R_{10}$  are taken together with N to form a) pyrrolidinyl or b) piperidinyl.

11. A compound of claim 10 wherein  $R_3$  and  $R_4$  are taken together with N to form het;

15 wherein het is a) pyrrolidinyl, b) piperidinyl or c) azetidinyl;  
the above het groups are optionally substituted with one  $R_7$ ;  
 $R_7$  is  $-CH_2-NR_9R_{10}$ ;  
 $R_9$  and  $R_{10}$  are each independently a) methyl or b) ethyl;  
or  $R_9$  and  $R_{10}$  are taken together with N to form a) pyrrolidinyl or b)

20 piperidinyl.

12. A compound of claim 1  
wherein  $R_1$  is a)  $-CH_2CH_2CH_3$ , b)  $-C\equiv C-CH_3$  or c)  $-CF_3$ ;  
 $R_2$  is a)  $-(C_1-C_6)alkyl$  or b)  $-(C_2-C_6)alkenyl$ ;  
 $R_3$  is a) hydrogen, b) methyl, c) ethyl, d) propyl or e) isopropyl;

25  $R_4$  is  $-(C_2-C_3)alkyl-NR_5R_6$ ;  
 $R_5$  and  $R_6$  are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

13. A compound of claim 12  
wherein  $R_2$  is a) methyl, b) ethyl, c) propyl, d) ethenyl, e) propenyl or f) butenyl;

30  $R_3$  is a) hydrogen, b) methyl or c) ethyl,  
 $R_5$  and  $R_6$  are each independently a) methyl or b) ethyl.

14. A compound of claim 1  
wherein  $R_1$  is a)  $-CH_2CH_2CH_3$ , b)  $-C\equiv C-CH_3$  or c)  $-CF_3$ ;  
 $R_2$  is a)  $-(C_1-C_6)alkyl$  or b)  $-(C_2-C_6)alkenyl$ ;

R<sub>3</sub> is a) hydrogen, b) methyl, c) ethyl, d) propyl or e) isopropyl;  
R<sub>4</sub> is -(C<sub>0</sub>-C<sub>4</sub>)alkyl-het;  
het is a) morpholinyl, b) pyrrolidinyl, c) piperidinyl or d) piperazinyl;  
the above het groups are optionally substituted with one or two R<sub>7</sub>;

5 R<sub>7</sub> is a) methyl, b) ethyl or c) -NR<sub>9</sub>R<sub>10</sub>;  
R<sub>9</sub> and R<sub>10</sub> are each independently methyl or ethyl.

15. A compound of claim 14  
wherein R<sub>2</sub> is a) methyl, b) ethyl, c) propyl, d) ethenyl, e) propenyl or f) butenyl;  
R<sub>3</sub> is a) hydrogen, b) methyl or c) ethyl;

10 R<sub>4</sub> is -(C<sub>2</sub>-C<sub>3</sub>)alkyl-het;  
het is a) morpholinyl or b) pyrrolidinyl;  
the above het groups are optionally substituted with one or two R<sub>7</sub>;  
wherein R<sub>7</sub> is a) methyl or b) ethyl.

16. A compound of claim 1

15. wherein R<sub>1</sub> is a) -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, b) -C≡C-CH<sub>3</sub> or c) -CF<sub>3</sub>;  
R<sub>2</sub> is a) -(C<sub>1</sub>-C<sub>5</sub>)alkyl or b) -(C<sub>2</sub>-C<sub>5</sub>)alkenyl;  
R<sub>3</sub> and R<sub>4</sub> are taken together with N to form het;  
het is a) piperazinyl, b) pyrrolidinyl or c) piperidinyl;  
the above het groups are optionally substituted with one or two R<sub>7</sub>;

20 R<sub>7</sub> is a) -(C<sub>1</sub>-C<sub>2</sub>)alkyl optionally substituted with one or two R<sub>8</sub>, b) -(C<sub>0</sub>-C<sub>2</sub>)alkyl-NR<sub>9</sub>R<sub>10</sub> or c) -Z-C(O)-NR<sub>9</sub>R<sub>10</sub>;  
R<sub>8</sub> is -OH;  
R<sub>9</sub> and R<sub>10</sub> are each independently a) hydrogen b) methyl or c) ethyl;  
or R<sub>9</sub> and R<sub>10</sub> are taken together with N to form a) pyrrolidinyl or b)

25 piperidinyl.

17. A compound of claim 16  
wherein R<sub>2</sub> is a) methyl, b) ethyl, c) propyl, d) ethenyl, e) propenyl or f) butenyl;  
het is a) pyrrolidinyl or b) piperidinyl;  
the above het groups are optionally substituted with one R<sub>7</sub>;

30 R<sub>7</sub> is -CH<sub>2</sub>-NR<sub>9</sub>R<sub>10</sub>;  
R<sub>9</sub> and R<sub>10</sub> are each independently a) methyl or b) ethyl;  
or R<sub>9</sub> and R<sub>10</sub> are taken together with N to form a) pyrrolidinyl or b)  
piperidinyl.

18. A compound of claim 1 wherein in Formula I -CH<sub>2</sub>-R<sub>2</sub> is ethenyl or ethynyl.

19. A compound of claim 4 selected from the group consisting of:  
carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;  
carbamic acid, [3-(dimethylamino)propyl]-, (4bS,7R,8aR)-

5 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester; and  
carbamic acid, [3-(diethylamino)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester.

20. A compound of claim 6 selected from the group consisting of:  
10 carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;  
carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester;

15 15 phenanthrenyl ester;  
carbamic acid, [3-(dimethylamino)propyl]ethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester; and  
carbamic acid, [2-(dimethylamino)ethyl]ethyl-, (4bS,7R,8aR)-

20 20 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester.

21. A compound of claim 8 selected from the group consisting of:  
carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

25 25 carbamic acid, [2-(1-piperidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;  
carbamic acid, [3-(hexahydro-1*H*-azepin-1-yl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

30 30 carbamic acid, [3-(1-pyrrolidinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;  
carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester;

carbamic acid, [2-(1-piperidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester;

carbamic acid, (1-ethyl-3-piperidinyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl;

5 carbamic acid, [(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

carbamic acid, [(1-ethyl-2-pyrrolidinyl)methyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-

10 phenanthrenyl ester;

carbamic acid, [3-(hexahydro-1*H*-azepin-1-yl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester;

carbamic acid, [(2*R*)-1-ethyl-2-pyrrolidinyl)methyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-

15 phenanthrenyl ester;

carbamic acid, [3-(1-piperidinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

carbamic acid, [3-(1-pyrrolidinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-

20 phenanthrenyl ester;

carbamic acid, [(2*S*)-1-ethyl-2-pyrrolidinyl)methyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester;

carbamic acid, [(2*R*)-1-ethyl-2-pyrrolidinyl)methyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-

25 phenanthrenyl ester;

carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

and

30 carbamic acid, [3-(4-morpholinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester.

22. A compound of claim 11 selected from the group consisting of:

1-pyrrolidinecarboxylic acid, 2-(1-pyrrolidinylmethyl)-, (4bS,7R,8aR)-  
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-  
phenanthrenyl ester;

1-piperidinecarboxylic acid, 2-(1-piperidinylmethyl)-, (4bS,7R,8aR)-

5 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-  
phenanthrenyl ester;

1-piperidinecarboxylic acid, 2-[(dimethylamino)methyl]-, (4bS,7R,8aR)-  
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-  
phenanthrenyl ester;

10 1-piperidinecarboxylic acid, 2-[(diethylamino)methyl]-, (4bS,7R,8aR)-  
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-  
phenanthrenyl ester; and

1-azetidinecarboxylic acid, 3-(1-piperidinyl)-, (4bS,7R,8aR)-

4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-  
phenanthrenyl ester;

15 15 phenanthrenyl ester.

23. Carbamic acid, (2,2,6,6-tetramethyl-4-piperidinyl)-, (4bS,7R,8aR)-  
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-  
phenanthrenyl ester, a compound of claim 7.

24. A compound of claim 13 selected from the group consisting of:

20 carbamic acid, (3-dimethylaminopropyl)methyl-, (4bS, 7R, 8aR)-  
4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl  
ester;

carbamic acid, (2-dimethylaminoethyl)methyl-, (4bS, 7R, 8aR)-

4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl  
25 ester;

carbamic acid, (2-dimethylaminoethyl)ethyl-, (4bS, 7R, 8aR)-

4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl  
ester; and

carbamic acid, (2-dimethylaminoethyl)-, (4bS, 7R, 8aR)-4b,5,6,7,8,8a,9,10-  
30 octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester.

25. A compound of claim 15 selected from the group consisting of:

carbamic acid, (3-morpholin-4-yl-propyl)-, (4bS, 7R, 8aR)-

4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl  
ester;

carbamic acid, (2-pyrrolidin-1-yl-ethyl)-, (4bS, 7R, 8aR)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester; and carbamic acid, (2-morpholin-4-yl-ethyl)-,(4bS, 7R, 8aR)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester.

5 26. 2-Pyrrolidin-1-ylmethyl/pyrrolidine-1-carboxylic acid, (4bS, 7R, 8aR)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynylphenanthren-2-yl ester, a compound of claim 17.

27. A method for the treatment of a glucocorticoid receptor-mediated disease or condition in a mammal, which comprises administering to the mammal a

10 therapeutically effective amount of a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug.

28. The method of claim 27 wherein the glucocorticoid receptor-mediated disease or condition is selected from the group consisting of obesity, diabetes, depression, anxiety and neurodegeneration.

15 29. The method of claim 28 wherein the condition is obesity.

30. The method of claim 29 which further comprises administering a  $\beta_3$  agonist, a thyromimetic agent, an eating behavior modifying agent or a NPY antagonist.

31. The method of claim 30 wherein the eating behavior modifying agent is orlistat or sibutramine.

20 32. The method of claim 28 wherein the disease is diabetes.

33. The method of claim 32 which further comprises administering an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, insulin, a sulfonylurea, glipizide, glyburide, or chlorpropamide.

34. The method of claim 27 wherein the glucocorticoid receptor-mediated

25 disease is an inflammatory disease.

35. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug; and a pharmaceutically acceptable carrier, vehicle or diluent.

30 36. A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising:

a first compound, said first compound being a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound, or prodrug;

a second compound, said second compound being a  $\beta_3$  agonist, a thyromimetic agent, an eating behavior modifying agent or a NPY antagonist; and a pharmaceutical carrier, vehicle or diluent.

37. A kit comprising:

5 a) a first compound, said first compound being a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound, or prodrug and a pharmaceutically acceptable carrier, vehicle or diluent in a first unit dosage form;

10 b) a second compound, said second compound being a  $\beta_3$  agonist, a thyromimetic agent, an eating behavior modifying agent or a NPY antagonist; and a pharmaceutically acceptable carrier, vehicle or diluent in a second unit dosage form; and

15 c) a container for containing said first and second dosage forms; wherein the amounts of said first and second compounds result in a therapeutic effect.

38. A method for inducing weight loss in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.

39. A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising:

20 a first compound, said first compound being a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug;

25 a second compound, said second compound being an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, insulin, a sulfonylurea, glipizide, glyburide, or chlorpropamide; and a pharmaceutical carrier, vehicle or diluent.

40. A method for the treatment of an inflammatory disease in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.

41. The method of claim 40 wherein the inflammatory disease is selected from the group consisting of arthritis, asthma, rhinitis and immunomodulation.